Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

August 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

docetaxel

Given in 3- or 4- week courses

DRUG

prednisone

Given in 3- or 4- week courses

Trial Locations (19)

7

Mater Misericordiae University Hospital, Dublin

8

St. James's Hospital, Dublin

9

Beaumont Hospital, Dublin

24

Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin

15850

Tampere University Hospital, Lahti

28500

Satakunta Central Hospital, Pori

33521

Tampere University Hospital, Tampere

48210

Kymenlaakso Central Hospital, Kotka

65185

Karlstad Central Hospital, Karlstad

67200

Keski-Pohjanmaa Central Hospital, Kokkola

87140

Kainuu Central Hospital, Kajaani

FIN-00029

Helsinki University Central Hospital, Helsinki

FIN-90014

Oulu University Hospital, Oulu

FIN-20521

Turku University Central Hospital, Turku

Unknown

Bons Secours Hospital, Cork

Mercy University Hospital, Cork

Galway University Hospital, Galway

0009

Mid-Western Cancer Centre at Mid-Western Regional Hospital, Limerick

S-171 76

Karolinska University Hospital - Solna, Stockholm

All Listed Sponsors
lead

Tampere University

OTHER

NCT00255606 - Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter